Bausch Health Companies Inc sees a modest uptick in its stock price amidst recent developments.
Bausch Health Companies Inc (BHC.TO) experienced a price increase of 1.62% today, closing at C$6.88. Over the past week, the stock has risen by 0.73%, although it remains down 30.65% year-to-date. Recent news from the company may have influenced this week's performance.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.53B
52W high
$11.97
52W low
$6.45
1W change
+0.73%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 1.9% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.01
+1.9% Upside
Current Price
C$6.88
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
50.1%
Annualized
90-Day Vol
42.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.75
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.48 | C$5.45 – C$7.71 |
| 60 trading days | C$6.11 | C$4.78 – C$7.80 |
| 90 trading days | C$5.75 | C$4.27 – C$7.76 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should note the recent developments regarding Bausch Health's product listings and upcoming earnings announcement, while also keeping an eye on the stock's technical indicators.
C$6.88 closing price with a 1D gain of 1.62%.
The stock has seen a substantial decline of 30.65% year-to-date, reflecting ongoing struggles for Bausch Health.
Bull case
The recent listing of PrOKEDI on the RAMQ formulary in Quebec could boost sales and improve market visibility, potentially leading to better financial performance in the future.
Bear case
Despite recent gains, the stock is still significantly below its 200-day moving average and has a negative profit margin, indicating ongoing challenges for the company.
Recent Company News
Bausch Health has made headlines recently with significant developments. On July 12, the Canadian subsidiary of Bausch Health listed PrOKEDI dosages in the RAMQ formulary, marking an important step as it expands its product offerings. This is particularly significant as Québec becomes the first province to include PrOKEDI, an extended-release injectable suspension of risperidone for treating schizophrenia, on its public drug reimbursement formulary. These announcements could enhance Bausch Health's market presence and sales. Additionally, the company is set to announce its second-quarter results on July 29, 2026, which may provide further insights into its financial performance.
Technical Picture
As of the latest close, Bausch Health's stock is trading at C$6.88, which is 4.8% below its 50-day moving average of C$7.23 and 16.6% below the 200-day moving average of C$8.25. The stock has a 52-week range of C$6.45 to C$11.97, currently sitting at about 8% of its range. With a beta of 0.42, the stock is less volatile than the broader market. Current trading volume stands at 260,374 shares, significantly lower than the 20-day average volume of 561,318 shares, indicating reduced investor activity.
Insider Activity
In recent insider activity, Michael Goettler resigned from Bausch Health's Board of Directors on July 1. Such changes in leadership can often lead to shifts in company strategy and investor sentiment.
Earnings Outlook
Analysts have a neutral outlook for Bausch Health, with an average target price of C$7.01, suggesting a potential upside of 1.9% from the current trading price. This reflects cautious optimism as the company works to navigate its challenges.
Price Action Summary
Bausch Health Companies Inc closed at C$6.88 today, reflecting a daily gain of 1.62%. While the stock has shown some recovery this week, it continues to face significant challenges, as evidenced by its year-to-date decline of 30.65%.
Advertisement
